FI4103178T3 - Menetelmiä fabryn taudin hoitamiseksi - Google Patents
Menetelmiä fabryn taudin hoitamiseksiInfo
- Publication number
- FI4103178T3 FI4103178T3 FIEP21753606.9T FI21753606T FI4103178T3 FI 4103178 T3 FI4103178 T3 FI 4103178T3 FI 21753606 T FI21753606 T FI 21753606T FI 4103178 T3 FI4103178 T3 FI 4103178T3
- Authority
- FI
- Finland
- Prior art keywords
- migalastat
- salt
- use according
- patient
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/42—Detecting, measuring or recording for evaluating the gastrointestinal, the endocrine or the exocrine systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Physiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062972392P | 2020-02-10 | 2020-02-10 | |
| PCT/US2021/017446 WO2021163183A1 (en) | 2020-02-10 | 2021-02-10 | Methods of treating fabry disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4103178T3 true FI4103178T3 (fi) | 2026-03-23 |
Family
ID=77272302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP21753606.9T FI4103178T3 (fi) | 2020-02-10 | 2021-02-10 | Menetelmiä fabryn taudin hoitamiseksi |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210251972A1 (https=) |
| EP (2) | EP4732901A2 (https=) |
| JP (1) | JP2023513700A (https=) |
| KR (1) | KR20220150902A (https=) |
| AU (1) | AU2021218578A1 (https=) |
| CA (1) | CA3167476A1 (https=) |
| DK (1) | DK4103178T3 (https=) |
| FI (1) | FI4103178T3 (https=) |
| LT (1) | LT4103178T (https=) |
| PT (1) | PT4103178T (https=) |
| WO (1) | WO2021163183A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3224546C (en) | 2017-05-30 | 2026-02-24 | Amicus Therapeutics, Inc. | Use of migalastat in the treatment of fabry patients |
| KR20200128676A (ko) | 2018-02-06 | 2020-11-16 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도 |
| US12594268B2 (en) * | 2018-08-20 | 2026-04-07 | Amicus Therapeutics, Inc. | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
| KR20220044560A (ko) | 2019-08-07 | 2022-04-08 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법 |
| US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| MX2009010557A (es) | 2007-03-30 | 2009-11-19 | Amicus Therapeutics Inc | Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas. |
| US9999618B2 (en) * | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| EP2946785B1 (en) | 2008-02-12 | 2018-10-24 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
| TW202408513A (zh) * | 2016-07-19 | 2024-03-01 | 美商阿米庫斯醫療股份有限公司 | 治療ert初治的和已經歷ert的患者中之法布瑞氏症 |
-
2021
- 2021-02-10 KR KR1020227030895A patent/KR20220150902A/ko active Pending
- 2021-02-10 WO PCT/US2021/017446 patent/WO2021163183A1/en not_active Ceased
- 2021-02-10 LT LTEPPCT/US2021/017446T patent/LT4103178T/lt unknown
- 2021-02-10 JP JP2022548459A patent/JP2023513700A/ja active Pending
- 2021-02-10 DK DK21753606.9T patent/DK4103178T3/da active
- 2021-02-10 PT PT217536069T patent/PT4103178T/pt unknown
- 2021-02-10 CA CA3167476A patent/CA3167476A1/en active Pending
- 2021-02-10 AU AU2021218578A patent/AU2021218578A1/en active Pending
- 2021-02-10 US US17/172,846 patent/US20210251972A1/en active Pending
- 2021-02-10 EP EP25226333.0A patent/EP4732901A2/en active Pending
- 2021-02-10 FI FIEP21753606.9T patent/FI4103178T3/fi active
- 2021-02-10 EP EP21753606.9A patent/EP4103178B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3167476A1 (en) | 2021-08-19 |
| LT4103178T (lt) | 2026-04-10 |
| EP4732901A2 (en) | 2026-04-29 |
| EP4103178A1 (en) | 2022-12-21 |
| DK4103178T3 (da) | 2026-03-30 |
| EP4103178B1 (en) | 2025-12-24 |
| AU2021218578A1 (en) | 2022-08-25 |
| PT4103178T (pt) | 2026-03-30 |
| US20210251972A1 (en) | 2021-08-19 |
| EP4103178A4 (en) | 2024-03-20 |
| KR20220150902A (ko) | 2022-11-11 |
| WO2021163183A1 (en) | 2021-08-19 |
| JP2023513700A (ja) | 2023-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI4103178T3 (fi) | Menetelmiä fabryn taudin hoitamiseksi | |
| López-Bescós et al. | Long-term safety and efficacy of ivabradine in patients with chronic stable angina. | |
| JP2023513700A5 (https=) | ||
| Alt et al. | A comparison of treatment of atrial fibrillation with low-energy intracardiac cardioversion and conventional external cardioversion | |
| JP3776931B2 (ja) | Ａｃｅ阻害剤ラミプリルとジヒドロピリジン化合物を含有する新規医薬組成物 | |
| Winniford et al. | Alpha-adrenergic blockade for variant angina: a long-term, double-blind, randomized trial. | |
| DiSegni et al. | Overdrive pacing in quinidine syncope and other long QT-interval syndromes | |
| Minami et al. | Effects of amlodipine and nifedipine retard on autonomic nerve activity in hypertensive patients | |
| IE65575B1 (en) | Use of baclofen for obtaining medicaments for the treatment of angina pectoris | |
| JP2020531550A5 (https=) | ||
| Plänitz | Comparison of moxonidine and clonidine HCl in treating patients with hypertension | |
| Veterans Administration Cooperative Study Group on Antihypertensive Agents et al. | Captopril: evaluation of low doses, twice-daily doses and the addition of diuretic for the treatment of mild to moderate hypertension | |
| Anderson et al. | Pirmenol for control of ventricular arrhythmias: oral dose-ranging and short-term maintenance study | |
| SI9620036B (sl) | Derivat aminotetralina za terapijo kardiovaskularnih bolezni | |
| Allely et al. | The effects of the novel anti‐anginal compound RS 43285 on myocardial conduction in the anaesthetized dog | |
| Brachmann et al. | Acute and chronic antiarrhythmic efficacy of d-sotalol in patients with sustained ventricular tachyarrhythmias | |
| Kennerdy et al. | Generalized seizures as the presentation of flecainide toxicity | |
| Uusitalo | Long Term Efficacy of a Controlled-Release Formulation of Isosorbide 5-Mononitrate (Imdur®) in Angina Patients Receivingβ-Blockers | |
| Kerin et al. | Mexiletine: long-term efficacy and side effects in patients with chronic drug-resistant potentially lethal ventricular arrhythmias | |
| Fiddes et al. | Evaluation of indapamide 1.25 mg once daily in elderly patients with mild to moderate hypertension | |
| Ruddy et al. | Comparison of ramipril and enalapril in patients with essential hypertension | |
| CA2276324C (en) | Loratadine for use as an antiarrhythmic | |
| Rothbart et al. | Clinical electrophysiology, efficacy and safety of chronic oral cibenzoline therapy in refractory ventricular tachycardia | |
| JP4032437B2 (ja) | 痴呆治療剤 | |
| EP0406327B1 (en) | Long lasting composition of propafenone and quinidine for treatment of cardiac conditions |